Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1535 - A Serum miRNA Biomarker Panel for the Detection of Early Stage Non-Small Cell Lung Cancer


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Lisha Ying


Annals of Oncology (2018) 29 (suppl_8): viii483-viii487. 10.1093/annonc/mdy290


L. Ying1, R. Zou2, L. Du3, L. Shi4, N. Zhang1, J. Jin1, J. Wu1, F. Zhang1, K. Chen1, M. Huang1, Y. Zhang5, A. Lin6, H. Yu7, L. Zhou2, W. Mao8, D. Su9

Author affiliations

  • 1 Zhejiang Cancer Hospital, Zhejiang cancer research institution, 310022 - Hangzhou/CN
  • 2 Mirxes(hangzhou) Biotechnology Co, MIRXES(hangzhou) biotechnology Co, 31000 - hangzhou/CN
  • 3 Zhejiang Cancer Hospital, Zhejiang Cancer Center, 310022 - Hangzhou/CN
  • 4 Zhejiang Cancer Hospital, Radiology Department, 310022 - Hangzhou/CN
  • 5 Zhejiang Cancer Hospital, Department of Clinical Laboratory, 310022 - Hangzhou/CN
  • 6 Taizhou Hospital Of Zhejiang Province, Human Tissue Bank/Medical Research Center, 317000 - taizhou/CN
  • 7 University Of Hawaii Cancer Center, University of Hawaii Cancer Center, hawaii/US
  • 8 Zhejiang Cancer Hospital, Department of Thoracic Surgery, hangzhou/CN
  • 9 Zhejiang Cancer Hospital, Department of Pathology, hangzhou/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1535


Non-small cell lung cancer is the most prevalent cancer and leading cause of cancer death worldwide. Low-dose spiral computed tomography (LDCT) scan is being recommended as a screening test for smokers in the US. However, the poor specificity of LDCT has raised significant concerns about its high chance of false positive results. This study aimed to develop a blood miRNA based molecular diagnostic test for the detection of early stage lung cancer.


The three-phase study was designed with a total of 948 cancer-free controls, and 768 patients with NSCLC. In the discovery phase, more than 400 miRNAs were profiled with MiRXES’s qPCR based high throughput assay platform through a highly defined Chinese male smoker case-control cohort (n = 424) where the cases were collected from Zhejiang Cancer Hospital and the controls were collected form the LDCT screening program in Zhejiang province, China. Differentially expressed miRNAs were further validated in another Chinese case-control cohort (n = 432) collected from similar sources and a white case-control cohort (n = 218) collected from the EU and US. Finally, the identified miRNAs were further assessed in three additional Asian cohorts: a Chinese cohort collected from the similar sources (n = 237), a Chinese cohort collected from independent sources (n = 340), and a Singaporean cohort (Chinese, Malay and Indian population) (n = 65).


29 miRNA biomarkers with p-value (FDR) <0.01 and more than one z-score (standardized score) difference were identified in the discovery phase. With multiple time of two-fold cross-validation, 5 miRNAs were found to be minimally required to form the biomarker panel for the accurate prediction of early stage lung cancer and the panel gives 0.936 (95% CI, 0.912-0.957) AUC for the Chinese validation cohort and 0.970 (95% CI, 0.939-0.986) AUC for the white validation cohort. The 5-miRNA biomarker panel were then further validated in three additional Asian cohorts, giving 0.973 (95% CI 0.950-0.986) AUC for similarly sourced Chinese cohort, 0.916 (95% CI, 0.852-0.949) AUC for the independently sourced Chinese cohort, and 0.911 (95% CI, 0.822-0.963) AUC for the Singaporean cohort, respectively.


The five-miRNA panel in serum may serve as a potential non-invasive biomarker in detecting early stage NSCLC.

Clinical trial identification

Legal entity responsible for the study

Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.